Literature DB >> 20489599

Effect of collagen cross-linking in stromal fibril organization in edematous human corneas.

Kátia Mantovani Bottós1, Ana Luisa Hofling-Lima, Manuela C Barbosa, Jose Bonifacio Barbosa, Juliana L Dreyfuss, Paulo Schor, Helena B Nader.   

Abstract

PURPOSE: To assess structural stromal modifications after riboflavin and UV-A exposure in edematous human corneas.
METHOD: Fourteen eyes with corneal edema were enrolled in the study. In the cross-linking (CXL) group, 7 corneal buttons were obtained from 6 patients who underwent penetrating keratoplasty (PK) 7-90 days after the CXL treatment. The control group was composed of 7 corneal buttons with bullous keratopathy. After the PK, stromal modifications were investigated using immunofluorescence in all corneal grafts. All patients had at least 3 months of corneal edema and were in the eye bank list waiting for keratoplasty.
RESULTS: All corneas in the treated group showed a pronounced lamellar zone of collagen fibers highly organized in the anterior stroma, but there was not complete homogeneity between the samples. Corneas with advanced disease and stromal fibrosis were less compacted than ones with mild disease severity. Similarly, those ones that underwent PK 3 months after CXL also showed a decreased effect compared with those with a reduced time between the CXL and the PK. DAPI staining demonstrated a complete fragmentation of keratocytes nuclei in the anterior stroma in all treated corneas, which were absent in the control group.
CONCLUSIONS: Our study showed an immediate effect of CXL with a limited long-term sustainability. Cross-linked corneas had a pronounced anterior zone of organized collagen fibers. Even the treated corneas with advanced bullous keratopathy and stromal fibrosis had histological evidence of collagen fibers organization, but this effect seems to be decreased compared with corneas in initial stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489599     DOI: 10.1097/ICO.0b013e3181bd9f12

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  In vitro effect of corneal collagen cross-linking on corneal hydration properties and stiffness.

Authors:  Georgios A Kontadakis; Harilaos Ginis; Nikolaos Karyotakis; Alexandros Pennos; Iro Pentari; George D Kymionis; Ioannis G Pallikaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-23       Impact factor: 3.117

2.  Acoustic radiation force for noninvasive evaluation of corneal biomechanical changes induced by cross-linking therapy.

Authors:  Raksha Urs; Harriet O Lloyd; Ronald H Silverman
Journal:  J Ultrasound Med       Date:  2014-08       Impact factor: 2.153

Review 3.  Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

Authors:  Maria Gkika; Georgios Labiris; Vassilios Kozobolis
Journal:  Int Ophthalmol       Date:  2011-08-17       Impact factor: 2.031

4.  The effects of riboflavin/ultraviolet: a corneal cross-linking on the signs and symptoms of bullous keratopathy.

Authors:  Hamid Gharaee; Mohammad-Reza Ansari-Astaneh; Fatemeh Armanfar
Journal:  Middle East Afr J Ophthalmol       Date:  2011-01

5.  Collagen cross-linking: current status and future directions.

Authors:  Marine Hovakimyan; Rudolf F Guthoff; Oliver Stachs
Journal:  J Ophthalmol       Date:  2012-01-12       Impact factor: 1.909

6.  Corneal Collagen Cross Linking (CXL) in treatment of Pseudophakic Bullous Keratopathy.

Authors:  Muhammad Saim Khan; Imran Basit; Mazhar Ishaq; Tariq Shakoor; Amer Yaqub; Rana Intisar
Journal:  Pak J Med Sci       Date:  2016 Jul-Aug       Impact factor: 1.088

7.  The effect of riboflavin/UVA collagen cross-linking therapy on the structure and hydrodynamic behaviour of the ungulate and rabbit corneal stroma.

Authors:  Sally Hayes; Christina S Kamma-Lorger; Craig Boote; Robert D Young; Andrew J Quantock; Anika Rost; Yasmeen Khatib; Jonathan Harris; Naoto Yagi; Nicholas Terrill; Keith M Meek
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.